Login
$IRD
$4.10 +$0.06 (1.49%) After hours

$IRD 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Results of Operations and Financial Condition

OPGx-BEST1 Cohort 2 Dosing Complete and Data Expected in Q1 2027

21 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

15 Oct 2026 8-K: Regulation FD Disclosure

Prediction of Retinal Sensitivity Changes Following Treatment in BEST Disease George Magrath, MD Retina in Rio 2026

11 Sep 2026 8-K: Regulation FD Disclosure

OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month Results September 9, 2026

09 Sep 2026 8-K: Regulation FD Disclosure; Other Events

OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month Results September 9, 2026

06 Aug 2026 8-K: Results of Operations and Financial Condition

OPGx-BEST1 Cohort 1 Topline Data Expected in Second Week of September 2026

16 Jun 2026 8-K: Regulation FD Disclosure

Rapidly Advancing Five IRD Programs​ with Four Clinical Data Readouts Expected in 2027

16 Jun 2026 8-K: Regulation FD Disclosure

Opus Genetics R&D Science Forum June 16, 2026 | 10:00 AM – 12:00 PM ET

12 May 2026 8-K: Results of Operations and Financial Condition

Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ET

24 Apr 2026 8-K: Creation of a Direct Financial Obligation

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

22 Apr 2026 8-K: Submission of Matters to a Vote of Security Holders

At the 2026 annual meeting of stockholders (the “Annual Meeting”) of Opus Genetics, Inc. (the “Company”), held on April 20, 2026, the Company’s stockholders (i) elected nine directors to the board of directors of the Company, each to ser...

07 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

Whereas, Opus Genetics Inc. (the “Company”) wishes to ensure that its executives, including [name and title of executive] (the “Executive”) avoid certain distractions related to parachute payment excise taxes in connection with any chang...

07 Apr 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This Note Purchase Agreement (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) is made and dated as of April 2, 2026 (the “Effective Date”) among the Purchasers listed on Schedule 1.1(a)...

10 Mar 2026 8-K: Results of Operations and Financial Condition

- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -

19 Feb 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +3 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 13, 2026, by and among Opus Genetics, Inc., a Delaware corporation (the “Company”), and the entities listed on Exhibit A attached to this Agreement (each, a “P...

12 Jan 2026 8-K: Regulation FD Disclosure

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning data from and future enrollment for ...

08 Jan 2026 8-K: Regulation FD Disclosure

- Multi-asset pipeline with significant targeted data readouts and milestones -

19 Dec 2025 8-K: Other Events

On December 17, 2025, Viatris Inc., the Company’s global commercialization partner for Phentolamine Ophthalmic Solution 0.75% (Phentolamine), filed a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FD...

12 Nov 2025 8-K: Results of Operations and Financial Condition

- Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated vision -

06 Nov 2025 8-K: Entry into a Material Definitive Agreement; Other Events

This Securities Purchase Agreement (this “Agreement”) is dated as of November 5, 2025, between Opus Genetics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support